Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$49.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Otsuka Pharmaceutical and H Lundbeck A/S to present new data on Brexpiprazole in major depressive disorder


Friday, 24 Jan 2014 02:15am EST 

H Lundbeck A/S:Says the first phase III data on Lundbeck and Otsuka Pharmaceutical's investigational compound brexpiprazole will be presented in an upcoming poster session at the 22nd European Psychiatry Association Congress (EPA) on Mar. 2.Says data will be presented from a completed phase III, randomized, placebo-controlled study investigating the effect of brexpiprazole as adjunctive therapy to antidepressant therapy in patients with major depressive disorder.Says data will include statistically significant improvements in mean MADRS (Montgomery-├ůsberg Depression Rating Scale) total score for patients receiving adjunctive brexpiprazole compared with placebo.Says data will include statistically significant advantage over placebo on all secondary endpoints.Says most common adverse events reported in the patients receiving adjunctive brexpiprazole were weight gain and akathisia (inner restlessness).Says over 90 percent of patients completed the randomized phase of the trial. 

Company Quote

136.5
0.7 +0.52%
22 May 2015